Jeffrey G Marblestone

Summary

Publications

  1. ncbi Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference
    Jeffrey G Marblestone
    Progenra Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    IDrugs 12:750-3. 2009
  2. ncbi Novel approach for characterizing ubiquitin E3 ligase function
    Jeffrey G Marblestone
    Progenra, Inc, Malvern, Pennsylvania, USA
    J Biomol Screen 15:1220-8. 2010
  3. ncbi Targeting the ubiquitin E3 ligase MuRF1 to inhibit muscle atrophy
    Michael J Eddins
    Progenra, Inc, 277 Great Valley Parkway, Malvern, PA 19355, USA
    Cell Biochem Biophys 60:113-8. 2011
  4. ncbi Deubiquitinating enzymes as novel anticancer targets
    Benjamin Nicholson
    Progenra, Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    Future Oncol 3:191-9. 2007
  5. ncbi Strategies for the identification of ubiquitin ligase inhibitors
    Seth J Goldenberg
    Progenra Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    Biochem Soc Trans 38:132-6. 2010

Detail Information

Publications5

  1. ncbi Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference
    Jeffrey G Marblestone
    Progenra Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    IDrugs 12:750-3. 2009
    ..Investigational drugs discussed include MLN-4924 and MLN-9708 (both Millennium Pharmaceuticals Inc), P-005091 (Progenra Inc), CEP-18770 (Cephalon Inc) and carfilzomib (Proteolix Inc)...
  2. ncbi Novel approach for characterizing ubiquitin E3 ligase function
    Jeffrey G Marblestone
    Progenra, Inc, Malvern, Pennsylvania, USA
    J Biomol Screen 15:1220-8. 2010
    ..As the number of E3 ligases associated with various disease states increases, the ability to quantitate the activity of these enzymes in an expeditious manner becomes imperative in drug discovery...
  3. ncbi Targeting the ubiquitin E3 ligase MuRF1 to inhibit muscle atrophy
    Michael J Eddins
    Progenra, Inc, 277 Great Valley Parkway, Malvern, PA 19355, USA
    Cell Biochem Biophys 60:113-8. 2011
    ..Thus MuRF1 can be targeted in a specific manner and produce positive results in cellular atrophy models...
  4. ncbi Deubiquitinating enzymes as novel anticancer targets
    Benjamin Nicholson
    Progenra, Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    Future Oncol 3:191-9. 2007
    ..In the following review, this fascinating class of regulatory enzymes will be described, and specific examples of DUBs that are viable targets for anticancer therapy will be considered...
  5. ncbi Strategies for the identification of ubiquitin ligase inhibitors
    Seth J Goldenberg
    Progenra Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    Biochem Soc Trans 38:132-6. 2010
    ..In this paper, we will discuss current platforms that report on E3 ligase activity and can detect E3 inhibitors, and underline the advantages and disadvantages of each approach...